Medical Developments International Limited (ASX: MVP) - ETF Exposure
Current share price for MVP : $0.485 0.025 (5.43%)+
Medical Developments International Limited (MVP) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a Company engaged in delivering emergency medical solutions. The Company manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product, used in hospital emergency departments, ambulance services, sports medicine and for analgesia during short surgical procedures.
MVP General Information +
| ASX Code | MVP |
| Website | N/A |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 54 |
| MVP Share Price | $0.485 |
| Day High | $0.485 |
| Day Low | $0.470 |
| Last Close | $0.460 |
| MVP Share Price Movement | $0.03 ( 5.43% ) |
Prices as at 16:40, 4 Sep 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Already own an Australian ETF? You may already have meaningful exposure to MVP
Medical Developments International Limited (MVP) is held across 1 ETF spanning strategies that include pharmaceuticals exposure . Its weighting in those funds means performance can have an outsized influence - when MVP moves, funds like DACE that hold it can move with it.
For more concentrated exposure, ETFs such as DACE (Dimensional Australian Core Equity (Managed Fund)) allocate about 0% to MVP , while the average exposure across all 1 ETF that hold it is around 0% .
Top ETF holdings
Last updated: ETF data and holdings as at 5 September 2026
Own MVP directly or through an ETF?
How does holding Medical Developments International Limited (MVP) shares directly compare to ETFs that include it?
|
MVP Direct
|
DACE
ASX |
|
|---|---|---|
| Holdings | 1 company | 485 holdings |
| MVP Weight | 100% | 0% |
| Diversification | Single Stock | Broad |
| Annual Cost | Brokerage only | 0.28% p.a. |
| Approx. Yield | 0% | 2.94% |
| Star Ratings | - |  |
Yields and costs are approximate. ETF yields reflect the fund's dividend distributions, not MVP's direct yield. Annual cost uses each ETF's MER.
MVP Exposure on $10,000 investment
How a $10,000 investment in Medical Developments International Limited (MVP) one week ago compares with ETFs that hold it.
| Security | Investment type | Current price | 7-day price movement | Dollar change | Value today |
|---|---|---|---|---|---|
| Medical Developments International Limited (MVP) | Direct share | $0.485 | 5.43% | +$543 | $10,543 |
| Dimensional Australian Core Equity (Managed Fund) (DACE) | Equity - Australia Strategy | $19.400 | -0.31% | -$31 | $9,969 |
Assumes $10,000 invested 7 days ago. Figures are based on price movement only and exclude distributions, fees and brokerage.
Medical Developments International Limited (MVP) ETFs
1 ETF hold Medical Developments International Limited (MVP).
| ETF | MVP Weight | MER | Yield |
|---|---|---|---|
| Dimensional Australian Core Equity (Managed Fund) (DACE) | 0% | 0.28% | 2.94% |
Medical Developments International Limited (MVP) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | 2¢ | 100% | 5 Mar 2020 | 17 Apr 2020 | - | - | - |
| HFResult | 2¢ | 100% | 3 Sep 2019 | 4 Oct 2019 | - | - | - |
| Result | 2¢ | 100% | 7 Mar 2019 | 17 Apr 2019 | - | - | - |
See all dividends from Medical Developments International Limited (MVP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Medical Developments International Limited (MVP) price-sensitive announcements
MVP - MVP Announces FY26 Full Year Results
Medical Developments International Limited announced its FY26 full year results, reporting
Medical Developments International Limited (MVP)
20 Aug 2026 | 8:56 AM
20 Aug 2026 | 8:56 AM
MVP - FY26 Full year Results Investor Presentation
Medical Developments International Limited reported a solid financial performance for FY26
Medical Developments International Limited (MVP)
20 Aug 2026 | 8:56 AM
20 Aug 2026 | 8:56 AM
MVP - FY26 Full Year Results
Medical Developments International Limited (MVP) reported its FY26 financial results for t
Medical Developments International Limited (MVP)
20 Aug 2026 | 8:55 AM
20 Aug 2026 | 8:55 AM
MVP - Appendix 4C and Quarterly Activity Report 30 June 2026
Medical Developments International Limited reported a positive free cash flow for Q4 and t
Medical Developments International Limited (MVP)
24 Jul 2026 | 8:24 AM
24 Jul 2026 | 8:24 AM
Medical Developments International Limited (MVP) Recent ASX Announcements
MVP Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | $0.63 | $0.50 | 488.90% | 99.60 | 0.00 | 0.00% | 0.0% |
| 2025A | $0.09 | $0.10 | -100.30% | 565.40 | 0.00 | 0.00% | 0.0% |
| 2024A | -$24.62 | -$27.80 | 34.80% | 0.00 | 0.00 | 0.00% | 0.0% |
MVP Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $847M | 0.4454 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Medical Developments International Limited (MVP) | $52M | 4.8889 | 0.0000 | 0.0000 | 86.7925 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,608M | -0.7857 | 0.2462 | 0.9655 | 88.3971 | 70.9310 | 36.0877 | 0.00% | 1.60% | 1.90% |
MVP Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Leon Hoare | Non-Executive Director | 27 Sep 2013 |
| Ms Christine Emmanuel-Donnelly | Non-Executive Director | 26 May 2020 |
| Mr Paul Townsend | Non-Executive Director | 30 May 2025 |
| Dr Russell Basser | Non-Executive Director | 31 Aug 2023 |
| Mr Mark Fladrich | Non-Executive Director, Non-Executive Chairman | 1 Apr 2025 |
Medical Developments International Limited (MVP) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 30 Oct 2025 | BASSER, Russell | Buy | Direct Shares | 40,000 | $0.706 | $28,227.000 |
| 30 Sep 2025 | FLADRICH, Mark | Buy | Direct Shares | 62,858 | $0.710 | $44,629.000 |
| 22 Sep 2025 | TOWNSEND, Paul | Buy | Direct Shares | 25,000 | $0.671 | $16,785.310 |
See all changes in directors' interest & trades for Medical Developments International Limited (MVP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
MVP Management
| Name | Position |
|---|---|
| Brent MacGregor | Chief Executive Officer |
| A James | Chief Financial Officer |
| Tara Eaton | Company Secretary,General Counsel |
MVP Calendar of Events
| Date | Event |
|---|---|
| 19 August 2027 | Report (Prelim) |
| 18 February 2027 | Report (Interim) |
| 07 September 2026 | Report (Annual) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
